Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Environmental Health Perspectives (Impact Factor: 7.98). 10/2005; 113(9):1209-11.
Source: PubMed


The enzyme delta-aminolevulinic acid dehydratase (ALAD), which catalyzes the second step of heme synthesis, can be inhibited by several chemicals, including lead, a potential risk factor for brain tumors, particularly meningioma. In this study we examined whether the ALAD G177C polymorphism in the gene coding for ALAD is associated with risk of intracranial tumors of the brain and nervous system. We use data from a case-control study with 782 incident brain tumor cases and 799 controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity to the hospital. Blood samples were drawn and DNA subsequently sent for genotyping for 73% of subjects. ALAD genotype was determined for 94% of these samples (355 glioma, 151 meningioma, 67 acoustic neuroma, and 505 controls). Having one or more copy of the ALAD2 allele was associated with increased risk for meningioma [odds ratio (OR) = 1.6; 95% confidence interval (CI), 1.0-2.6], with the association appearing stronger in males (OR = 3.5; 95% CI, 1.3-9.2) than in females (OR = 1.2; 95% CI, 0.7-2.2). No increased risk associated with the ALAD2 variant was observed for glioma or acoustic neuroma. These findings suggest that the ALAD2 allele may increase genetic susceptibility to meningioma.

Download full-text


Available from: Preetha Rajaraman, Sep 15, 2014
17 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: delta-Aminolevulinic acid dehydratase (ALAD) catalyzes the second step of heme synthesis. The ALAD gene shows a polymorphism (G-to-C transversion at position 177) leading to 2 alleles (ALAD1 and ALAD2) and 3 phenotypes (ALAD 1-1, ALAD 1-2 and ALAD 2-2). This polymorphism has been shown to affect lead toxicity and the risk of meningioma. In addition, there is little evidence showing interethnic differences in the distribution this polymorphism, especially in heterogeneous populations such as the present-day Brazilian population. We examined the distribution of genetic variants of the G177C ALAD polymorphism in black and white Brazilians. We studied 115 subjects self-reported as black and 119 subjects as white (total N=234; 135 men and 99 women; age range: 18-60 years). Genomic DNA was extracted from venous blood and the genotypes for the ALAD polymorphism were determined by PCR followed by RFLP digestion and gel electrophoresis. We found a notable interethnic disparity in the distribution of G177C ALAD genotypes and alleles. The ALAD2 allele was more common in whites (12%) than in blacks (4%) (P<0.05). Correspondingly, the heterozygote (ALAD 1-2) or homozygote variant (ALAD 2-2) genotypes for this polymorphism were more common in whites than in blacks (P<0.05). The significant interethnic differences in the distribution of G177C ALAD variants found in the Brazilian population is consistent with differences previously reported in other countries. These findings may help us understand the interethnic disparities in susceptibility to lead toxicity and brain tumors.
    Clinica Chimica Acta 05/2006; 367(1-2):192-5. DOI:10.1016/j.cca.2005.12.009 · 2.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To study the association between the A to G transition at the -181-bp position in the promoter of matrix metalloproteinase-7 gene (MMP-7-181A/G) and susceptibility to adult astrocytoma, the MMP-7-181A/G polymorphism was genotyped by PCR-RFLP analysis among 221 adult astrocytoma patients and 366 healthy controls in a population of northern China. The result showed that the overall distribution of the MMP-7 genotypes among astrocytoma patients and healthy controls was significantly different (P<0.001). Compared with the A/A genotype, the G/G genotype significantly increased the risk to the development of astrocytoma (age and gender adjusted OR=2.77, 95% CI=1.27-6.02), while the MMP-7 A/G genotype only marginally increased the risk of developing this cancer (age and gender adjusted OR=1.66, 95% CI=0.99-2.84). Stratification analysis showed that the G/G genotype significantly increased the risk of astrocytoma only among male subjects (age adjusted OR=3.24, 95% CI=1.12-9.41) and individuals younger than 45 years (age and gender adjusted OR=3.16, 95% CI=1.09-9.16). When stratified by histological grades, a significant higher risk for developing grade II astrocytoma was observed among individuals harboring the A/G genotype (age and gender adjusted OR=2.06, 95% CI=1.05-4.05), while an about 3-fold elevation of risk to develop grades II, III, and IV astrocytomas was observed among individuals with the G/G genotype. The present result, for the first time, suggested that the MMP-7-181A/G polymorphism might be associated with the susceptibility to adult astrocytoma.
    Brain Research 12/2006; 1118(1):6-12. DOI:10.1016/j.brainres.2006.08.007 · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The single nucleotide polymorphisms (SNPs) in the promoter region of matrix metalloproteinase (MMP) genes may influence tumor occurrence and progression via modifying mRNA transcription and protein expression. The study aims to explore the association of the SNPs in MMP-1, 3 and MMP-9 promoters with susceptibility to adult brain astrocytoma in northern China. Genotyping for the MMP-1 -1607 2G/1G, MMP-3 -1171 5A/6A, and MMP-9 -1562 C/T SNPs were performed by PCR-RFLP methods among 236 adult astrocytoma patients and 366 healthy controls. The results showed that the overall distribution of the MMP-1 allelotype and genotype among astrocytoma patients and healthy controls was significantly different (P = 0.002 and P < 0.001, respectively). Compared with the 2G/2G genotype, the 1G/1G genotype significantly decreased the risk of astrocytoma development (adjusted OR = 0.58, 95% CI = 0.42-0.79). The similar results were obtained when stratified by gender and age at tumor diagnosis (< or =45 or >45 years). The association between MMP-3 -1171 5A/6A or MMP-9 -1562 C/T SNPs and susceptibility to astrocytoma was not observed in this study. However, MMP-1 1G-MMP-3 6A haplotype significantly reduced the risk of astrocytoma development when using MMP-1 2G-MMP-3 6A haplotype as a reference (OR = 0.45, 95% CI = 0.29-0.67). The present study suggested that, the MMP-1 -1607 1G/1G genotype and MMP-1 1G-MMP-3 6A haplotype may play protective role in the development of adult astrocytoma in northern Chinese, whereas the MMP-3 -1171 5A/6A and MMP-9 -1562 C/T polymorphisms may not be independent factors to influence susceptibility to adult astrocytoma in this population.
    Journal of Neuro-Oncology 10/2007; 85(1):65-73. DOI:10.1007/s11060-007-9392-5 · 3.07 Impact Factor
Show more